Selective vulnerability in neurodegeneration: Insights from clinical variants of Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 9, 2016, Pages 1000-1004

  Mattsson, Niklas ^a   Schott, Jonathan M ^b   Hardy, John ^b   Turner, Martin R ^c   Zetterberg, Henrik ^b,d  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer'S DISEASE

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; TAR DNA BINDING PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BRAIN CORTEX ATROPHY; CHEMICAL MODIFICATION; CORTICOBASAL SYNDROME; DEFAULT MODE NETWORK; GENE EXPRESSION; HUMAN; LOGOPENIC VARIANT OF PRIMARY PROGRESSIVE APHASIA; N TERMINAL TRUNCATION; NERVE CELL LESION; NEUROCHEMISTRY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; PYROGLUTAMATE MODIFICATION; REVIEW; TOXICITY; AMYLOID PLAQUE; BRAIN; DEGENERATIVE DISEASE; GENETICS; NERVE CELL; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHENOTYPE;

ALZHEIMER DISEASE; BRAIN; HUMANS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEURONS; PHENOTYPE; PLAQUE, AMYLOID;

EID: 84979791955     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311321     Document Type: Review

References (64)

1. Warren JD, Fletcher PD, Golden HL. The paradox of syndromic diversity in Alzheimer disease. Nat Rev Neurol 2012; 8: 451-64.
2. Ossenkoppele R, Pijnenburg YA, Perry DC, et al. The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. Brain 2015; 138 (Pt 9): 2732-49.
3. Ahmed S, De Jager CA, Haigh AM, et al. Logopenic aphasia in Alzheimers disease: clinical variant or clinical feature? J Neurol Neurosurg Psychiatry 2012; 83: 1056-62.
4. Crutch SJ, Lehmann M, Schott JM, et al. Posterior cortical atrophy. Lancet Neurol 2012; 11: 170-8.
5. Grijalvo-Perez AM, Litvan I. Corticobasal degeneration. Semin Neurol 2014; 34: 160-73.
6. Baron JC, Yamauchi H, Fujioka M, et al. Selective neuronal loss in ischemic stroke and cerebrovascular disease. J Cereb Blood Flow Metab 2014; 34: 2-18.
7. Fehm HL, Kern W, Peters A. The selfish brain: competition for energy resources. Prog Brain Res 2006; 153: 129-40.
8. Polymenidou M, Cleveland DW. Prion-like spread of protein aggregates in neurodegeneration. J Exp Med 2012; 209: 889-93.
9. Yang S, Huang S, Gaertig MA, et al. Age-dependent decrease in chaperone activity impairs MANF expression, leading to Purkinje cell degeneration in inducible SCA17 mice. Neuron 2014; 81: 349-65.
10. McCarthy A, Lonergan R, Olszewska DA, et al. Closing the tau loop: the missing tau mutation. Brain 2015; 138 (Pt 10): 3100-9.
11. Hof PR, Morrison JH. The aging brain: morphomolecular senescence of cortical circuits. Trends Neurosci 2004; 27: 607-13.
12. Reiman EM. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments. Neurobiol Aging 2011; 32 (Suppl 1): S44-7.
13. Bezprozvanny I, Mattson MP. Neuronal calcium mishandling and the pathogenesis of Alzheimer's disease. Trends Neurosci 2008; 31: 454-63.
14. Wasling P, Daborg J, Riebe I, et al. Synaptic retrogenesis and amyloid-beta in Alzheimer's disease. J Alzheimers Dis 2009; 16: 1-14.
15. Saxena S, Caroni P. Selective neuronal vulnerability in neurodegenerative diseases: from stressor thresholds to degeneration. Neuron 2011; 71: 35-48.
16. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
17. Ryan NS, Rossor MN. Defining and describing the pre-dementia stages of familial Alzheimer's disease. Alzheimers Res Ther 2011; 3: 29.
18. Schott JM, Warren JD. Alzheimer's disease: mimics and chameleons. Pract Neurol 2012; 12: 358-66.
19. Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young-onset dementia. Lancet Neurol 2010; 9: 793-806.
20. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol 2008; 63: 709-19.
21. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol 1988; 45: 789-93.
22. Hassan A, Whitwell JL, Josephs KA. The corticobasal syndrome-Alzheimer's disease conundrum. Expert Rev Neurother 2011; 11: 1569-78.
23. Kamenetz F, Tomita T, Hsieh H, et al. APP processing and synaptic function. Neuron 2003; 37: 925-37.
24. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. Nat Neurosci 2011; 14: 750-6.
25. Brody DL, Magnoni S, Schwetye KE, et al. Amyloid-beta dynamics correlate with neurological status in the injured human brain. Science 2008; 321: 1221-4.
26. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005; 25: 7709-17.
27. Jagust WJ, Mormino EC. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends Cogn Sci (Regul Ed) 2011; 15: 520-6.
28. Walker LC, Jucker M. Neurodegenerative diseases: expanding the prion concept. Annu Rev Neurosci 2015; 38: 87-103.
29. Myers N, Pasquini L, Göttler J, et al. Within-patient correspondence of amyloid-beta and intrinsic network connectivity in Alzheimer's disease. Brain 2014; 137 (Pt 7): 2052-64.
30. de Souza LC, Corlier F, Habert MO, et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain 2011; 134 (Pt 7): 2036-43.
31. Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136 (Pt 3): 844-58.
32. Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 2011; 76: 1789-96.
33. Teng E, Yamasaki TR, Tran M, et al. Cerebrospinal fluid biomarkers in clinical subtypes of early-onset Alzheimer's disease. Dement Geriatr Cogn Disord 2014; 37: 307-14.
34. Rabinovici GD, Furst AJ, Alkalay A, et al. Increased metabolic vulnerability in earlyonset Alzheimer's disease is not related to amyloid burden. Brain 2010; 133 (Pt 2): 512-28.
35. Ossenkoppele R, Mattsson N, Teunissen CE, et al. Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. Neurobiol Aging 2015; 36: 2340-7.
36. Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology 2009; 73: 1571-8.
37. Bird TD, Stranahan S, Sumi SM, et al. Alzheimer's disease: choline acetyltransferase activity in brain tissue from clinical and pathological subgroups. Ann Neurol 1983; 14: 284-93.
38. Rossor MN, Iversen LL, Reynolds GP, et al. Neurochemical characteristics of early and late onset types of Alzheimer's disease. Br Med J (Clin Res Ed) 1984; 288: 961-4.
39. Gorno-Tempini ML, Brambati SM, Ginex V, et al. The logopenic/phonological variant of primary progressive aphasia. Neurology 2008; 71: 1227-34.
40. Sha SJ, Ghosh PM, Lee SE, et al. Predicting amyloid status in corticobasal syndrome using modified clinical criteria, magnetic resonance imaging and fluorodeoxyglucose positron emission tomography. Alzheimers Res Ther 2015; 7: 8.
41. Whitwell JL, Jack CR Jr, Przybelski SA, et al. Temporoparietal atrophy: a marker of AD pathology independent of clinical diagnosis. Neurobiol Aging 2011; 32: 1531-41.
42. Lehmann M, Barnes J, Ridgway GR, et al. Global gray matter changes in posterior cortical atrophy: a serial imaging study. Alzheimers Dement 2012; 8: 502-12.
43. Migliaccio R, Agosta F, Possin KL, et al. Mapping the progression of atrophy in early- and late-onset Alzheimer's disease. J Alzheimers Dis 2015; 46: 351-64.
44. Mitchell TW, Mufson EJ, Schneider JA, et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease. Ann Neurol 2002; 51: 182-9.
45. Ossenkoppele R, Schonhaut DR, Baker SL, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol 2015; 77: 338-42.
46. Buerger K, Ewers M, Pirttilä T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 2006; 129 (Pt 11): 3035-41.
47. Seppälä TT, Nerg O, Koivisto AM, et al. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 2012; 78: 1568-75.
48. Nag S, Yu L, Capuano AW, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer's disease. Ann Neurol 2015; 77: 942-52.
49. Schneider JA, Arvanitakis Z, Yu L, et al. Cognitive impairment, decline and fluctuations in older community-dwelling subjects with Lewy bodies. Brain 2012; 135 (Pt 10): 3005-14.
50. Josephs KA, Whitwell JL, Weigand SD, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol 2014; 127: 811-24.
51. Feneberg E, Steinacker P, Lehnert S, et al. Limited role of free TDP-43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener 2014; 15: 351-6.
52. Magdalinou N, Lees AJ, Zetterberg H. Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 2014; 85: 1065-75.
53. Laforce R Jr, Tosun D, Ghosh P, et al. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology. Neuroimage Clin 2014; 4: 508-16.
54. Lehmann M, Madison CM, Ghosh PM, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proc Natl Acad Sci USA 2013; 110: 11606-11.
55. Miller ZA, Mandelli ML, Rankin KP, et al. Handedness and language learning disability differentially distribute in progressive aphasia variants. Brain 2013; 136 (Pt 11): 3461-73.
56. Yokoyama JS, Sirkis DW, Miller BL. C9ORF72 hexanucleotide repeats in behavioral and motor neuron disease: clinical heterogeneity and pathological diversity. Am J Neurodegener Dis 2014; 3: 1-18.
57. Eisen A, Turner MR, Lemon R. Tools and talk: an evolutionary perspective on the functional deficits associated with amyotrophic lateral sclerosis. Muscle Nerve 2014; 49: 469-77.
58. Eisen A, Turner MR. Does variation in neurodegenerative disease susceptibility and phenotype reflect cerebral differences at the network level? Amyotroph Lateral Scler Frontotemporal Degener 2013; 14 (7-8): 487-93.
59. Buell AK, Dobson CM, Knowles TP. The physical chemistry of the amyloid phenomenon: thermodynamics and kinetics of filamentous protein aggregation. Essays Biochem 2014; 56: 11-39.
60. Tarasoff-Conway JM, Carare RO, Osorio RS, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol 2015; 11: 457-70.
61. Lyons B, Kwan AH, Jamie J, et al. Age-dependent modification of proteins: N-terminal racemization. FEBS J 2013; 280: 1980-90.
62. Sandberg MK, Al-Doujaily H, Sharps B, et al. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 2011; 470: 540-2.
63. Eisenberg D, Jucker M. The amyloid state of proteins in human diseases. Cell 2012; 148: 1188-203.
64. Portelius E, Lashley T, Westerlund A, et al. Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry. Neurodegener Dis 2015; 15: 50-7.